Skip Navigation
Leading research to understand, treat, and prevent infectious, immunologic, and allergic diseases
Skip Website Tools
Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

HIV and Emerging Infectious Diseases Program

RPHI Study​

Study Name

Leukapheresis Procedures to Obtain Plasma and Lymphocytes for Research Studies on Antiretroviral Naïve HIV-Infected Patients

Study Number


Goal of Study

The National Institutes of Health is conducting a research study to evaluate volunteers either at the acute (early signs and symptoms of HIV infection and/or less than four months of known HIV exposure) and chronic stage (greater than six months or determinate positive result) of HIV-infection, who have elected to begin antiretroviral therapy (ART). The ART is to be provided by participant's Primary Care Provider. The study will require that patients consent to leukapheresis once before antiretroviral therapy and several times after suppression of plasma viremia (when the viral load is <50). We hope to further understand the mechanism(s) involved in maintenance of immune function following early intervention with ART.

Study Regimen

We will collect white blood cells by a process called leukapheresis, a standard blood collection procedure. Leukapheresis will remove white cells first, and then replace the red cells, through the same needle, or through a needle in your other arm. Volunteers will be compensated.

Eligibility Criteria

  • You are age 18 and older, with documented HIV-infection.
  • You have adequate veins for blood draws and apheresis.
  • Your viral load is >10,000 (if infection is primary).
  • Your platelets are >50,000.
  • You are not pregnant.
  • You are not currently abusing alcohol or drugs.

back to top

Last Updated October 26, 2011